85 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
. This agreement gives YOFOTO an exclusive 15-year geographic license to develop and market the Company's RCT-01 tendon regeneration technology … party. This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan, China, South
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
gives YOFOTO an exclusive 15-year geographic license to develop and market the Company's RCT-01 tendon regeneration technology in Greater China (China … . This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
to develop and market the Company's RCT-01 tendon regeneration technology in Greater China (China, Hong Kong, Macau, and Taiwan).
Intellectual Property … developed by either party. This agreement gave Shiseido an exclusive geographic license to use the Company's RCH-01 hair regeneration technology in Japan
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
geographic license to develop and market the Company’s RCT-01 tendon regeneration technology in Greater China (China, Hong Kong, Macau, and Taiwan … RCH-01 hair regeneration technology in Japan, China, South Korea, Taiwan and the ASEAN countries representing a population of approximately 2.1
20-F/A
6xpd su8g
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
puegjtn
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.2
cb1tz0pz
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.3
neyxa
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.1
ckx7lw ay0xab21vfx8k
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99.4
7aq6dxts8jsz15w53km
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
nwhvhf6tpzqr8
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
xwydl s9lci
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
qxiiufr
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
85xpgv
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
esal0
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.2
zfn1xjmtxjagbyf
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
xb9im32z
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.2
9tow9xdafj9m75h
18 Aug 21
Current report (foreign)
12:20pm